查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016213

快速診斷市場：全球市場按產品類型、技術、最終用戶和應用分類的預測 - 2026-2032 年

Rapid Diagnostics Market by Product Type, Technology, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，快速診斷市場價值將達到 190.8 億美元，到 2026 年將成長至 210.1 億美元，到 2032 年將達到 486.5 億美元，複合年成長率為 14.30%。

主要市場統計數據
基準年 2025 190.8億美元
預計年份：2026年 210.1億美元
預測年份 2032 486.5億美元
複合年成長率 (%) 14.30%

對影響快速診斷的趨勢進行了權威說明，並解釋了為什麼在創新、監管和供應鏈之間進行策略協調現在至關重要。

快速診斷領域正處於臨床緊迫性、技術創新和不斷演變的醫療服務模式的交匯點，這要求價值鏈上的相關人員制定清晰的策略方向。分子檢測、即時檢測平台和檢測化學的最新進展加速了檢測的去中心化，使得在傳統實驗室之外也能進行早期檢測和快速臨床決策。同時，來自支付方的壓力和臨床醫生的期望正在重新定義部署標準，處理能力、週轉時間和可操作的結果報告已成為關鍵績效指標。

檢測技術、數位化整合、監管變革和供應鏈韌性等方面的整合進步如何重塑診斷的部署。

診斷領域正經歷著一場變革性的轉變，技術、監管和市場力量的整合正在重新定義檢測的方式和地點。在技​​術層面，核酸擴增技術的進步、檢測設備的微型化以及電子讀取器的改進，正推動快速分子檢測從中心檢查室走向臨床應用。同時，改良的側向層析法和免疫檢測法提高了檢測的靈敏度和易用性，使其更適用於分散式應用。此外，數位化連接和雲端分析正在將個體檢測結果轉化為可操作的群體層面洞察，從而促進遠端臨床醫生的監督。

評估美國不斷變化的關稅政策對快速診斷產業在營運、財務和供應鏈方面的廣泛影響，展望 2025 年及以後。

近期貿易政策調整和關稅措施增加了全球快速診斷供應鏈的複雜性，其累積影響將持續到2025年，波及採購、製造和定價等各個環節。設備和耗材常用零件的進口關稅上調，推高了接收成本，並可能擠壓製造商的利潤空間，促使他們重新談判契約，並重新審視各銷售管道的定價策略。為此，供應商正在探索替代採購管道，實現部分生產的本地化，並重新設計物料材料清單（BOM），以減少對關稅敏感原料的依賴。

將產品分類、檢測技術、最終用戶需求和臨床應用與策略性產品和市場發布選擇聯繫起來的詳細細分見解。

為了深入了解市場，必須專注於不同的產品類別、技術模式、終端用戶環境和臨床應用，每種類別都有其獨特的市場接受趨勢和營運限制。產品細分清楚地展現了儀器、試劑和耗材以及檢測套組之間的差異。儀器既包括適用於集中式檢查室的桌上型系統，也包括分散式或照護現場環境最佳化的攜帶式設備。這種差異會影響醫療機構的採購週期、維護需求和資本投資計畫。

美洲、歐洲、中東和非洲以及亞太地區的區域市場動態決定了採用、監管和供應策略的差異。

區域趨勢對需求模式、監管預期和供應鏈策略有顯著影響，美洲、歐洲、中東和非洲以及亞太地區的趨勢各不相同。在美洲，對支援醫院網路和門診系統的整合平台的需求日益成長，採購受到支付方報銷規則以及對診斷設備和電子健康記錄 (EHR) 之間互通性的強烈需求的影響。該地區也積極投資國內製造業產能和官民合作關係，以加強供應鏈。

在快速診斷領域，塑造平台整合、夥伴關係模式和製造韌性的企業級競爭和策略行動。

快速診斷領域的競爭格局由成熟的跨國製造商、細分領域的專業公司、試劑供應商和數位化原生平台供應商組成，每家公司都奉行著自己獨特的策略。成熟的製造商利用其規模、豐富的產品系列和完善的分銷網路服務於醫院系統和實驗室，而小規模的創新者則專注於創新的檢測方式、精簡的生產流程或數位醫療功能的整合，旨在搶佔快速成長的細分市場。

為診斷領域的領導者提供切實可行的策略建議，以加強其產品組合、確保其價值鏈、展現臨床價值並拓展經營模式。

診斷產業的領導者必須將市場洞察轉化為具體行動，抓住機遇，並降低風險。首先，企業應優先考慮在儀器、試劑和檢測套組方面實現產品組合多元化，同時確保平台相容性，以最大限度地發揮產品應用潛力。投資於模組化設計和平台通用將縮短開發週期，並實現靈活的生產響應。其次，應透過多元化採購、地域多角化和策略性庫存緩衝來重新評估供應鏈策略，以降低貿易政策波動和物流瓶頸帶來的風險。

採用嚴謹的混合方法研究途徑，結合關鍵相關人員的訪談、第二手資料的整合、供應鏈映射和情境建模，以獲得可靠的見解。

這些研究成果透過與關鍵相關人員的對話、結構化的二次分析以及有針對性的情境建模，從多角度展現了快速診斷的現狀。主要資訊來自對臨床醫生、檢查室經理、採購專家和行業高管的訪談，從而獲得了關於工作流程優先級、推廣障礙和技術觀點的第一手觀點。二次分析整合了監管指南、已發表的臨床文獻、專利趨勢和公共發展，將市場觀察置於科學和合規的框架內。

全面概述了診斷技術創新、營運韌性、監管合規性和商業性執行之間面臨的策略挑戰。

總之，快速診斷生態系統呈現出機會與挑戰並存的複雜局面，需要清晰的策略規劃、強大的營運韌性和基於實證的商業化。分子診斷技術的進步、側向層析方法的改進以及攜帶式設備的普及，正在擴大檢測的覆蓋範圍，並使在傳統檢查室之外進行更快速的臨床干預成為可能。同時，監管變化、支付方的期望以及貿易政策趨勢，也為研發商和經銷商帶來了新的限制和挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：快速診斷市場：依產品類型分類

  • 裝置
    • 固定式
    • 可攜式的
  • 試劑和耗材
  • 檢測套組

第9章：快速診斷市場：依技術分類

  • 免疫檢測
  • 橫向流動化驗
    • 競爭型
    • 三明治法
  • 分子診斷
    • 等溫擴增
    • PCR

第10章 快速診斷市場：依最終使用者分類

  • 診所
  • 居家照護
  • 醫院
  • 檢查室

第11章 快速診斷市場：依應用領域分類

  • 心臟標記物
    • 肌酸激酶 Mb
    • 肌紅蛋白
    • 肌鈣蛋白
  • 糖尿病
    • 1型糖尿病
    • 2型糖尿病
  • 感染疾病
    • 細菌感染疾病
    • 寄生蟲感染疾病
    • 病毒感染疾病
  • 腫瘤學

第12章 快速診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 快速診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 快速診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國快速診斷市場

第16章：中國快速診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • EKF Diagnostics Holdings plc
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • QIAGEN NV
  • QuidelOrtho Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-035AB9C0DA79

The Rapid Diagnostics Market was valued at USD 19.08 billion in 2025 and is projected to grow to USD 21.01 billion in 2026, with a CAGR of 14.30%, reaching USD 48.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.08 billion
Estimated Year [2026] USD 21.01 billion
Forecast Year [2032] USD 48.65 billion
CAGR (%) 14.30%

An authoritative introduction to the dynamics shaping rapid diagnostics and why strategic alignment across innovation, regulation and supply chains matters now

The rapid diagnostics space sits at the intersection of clinical urgency, technological innovation, and shifting healthcare delivery models, demanding clear strategic orientation from stakeholders across the value chain. Recent advances in molecular assays, point-of-care platforms, and assay chemistries have accelerated the decentralization of testing, enabling earlier detection and faster clinical decision making outside traditional laboratory settings. Meanwhile, payer pressures and clinician expectations are reshaping the criteria for adoption, elevating throughput, turnaround time, and actionable result reporting as primary performance metrics.

As a consequence, manufacturers and service providers are navigating a more complex set of requirements: tighter regulatory scrutiny, rising demands for interoperability, and new business models that extend beyond product sales into data services and managed solutions. This environment favors organizations that can combine robust clinical validation with scalable manufacturing and resilient supply chains. At the same time, end users-from hospitals to home care-are increasingly motivated to integrate diagnostic outputs into clinical workflows and population health programs, which creates demand for flexible platforms and validated point-of-care assays.

In short, the introduction to this landscape emphasizes the need for informed strategic responses that bridge innovation, compliance, and commercial execution across multiple product and technology categories, while maintaining patient-centric outcomes and operational efficiency.

How convergent advances in assay technology, digital integration, regulatory evolution, and supply chain resilience are reshaping diagnostic deployment

The diagnostic landscape is undergoing transformative shifts driven by convergent technological, regulatory, and market forces that are redefining how and where tests are performed. Technologically, improvements in nucleic acid amplification methods, assay miniaturization, and readout electronics have enabled rapid molecular testing to move from centralized labs to point-of-care settings, while enhanced lateral flow formats and immunoassays have improved sensitivity and usability for decentralized applications. Simultaneously, digital connectivity and cloud-based analytics are turning discrete test results into actionable population-level insights and facilitating remote clinician oversight.

Regulatory pathways are also evolving to accommodate novel device formats and software-as-a-medical-device components, which accelerates time to market for well-documented platforms but raises compliance complexity for integrated solutions. Commercially, reimbursement frameworks and procurement preferences are shifting toward outcomes-based purchasing and bundled services, prompting vendors to rethink go-to-market approaches and strategic partnerships. Supply chain resilience has moved from a cost focus to a strategic imperative, with manufacturers diversifying sourcing and investing in regional production capabilities to mitigate disruption risk.

Taken together, these transformative shifts favor agile organizations that can align product innovation with clinical validation, regulatory foresight, and scalable manufacturing, while engaging payers and providers to demonstrate real-world value across care settings.

Assessing the broader operational, financial, and supply chain consequences of evolving United States tariff policies on rapid diagnostics through 2025 and beyond

Trade policy adjustments and tariff measures instituted in recent years have imposed a layer of complexity on global supply chains for rapid diagnostics, and their cumulative effect continues to reverberate through procurement, manufacturing, and pricing decisions into 2025. Increased import duties on components commonly used in instruments and consumables can elevate landed costs and squeeze manufacturer margins, prompting contract renegotiations and a reassessment of pricing strategies across commercial channels. In response, suppliers are evaluating alternative sourcing, localizing portions of production, and redesigning product bill-of-materials to reduce exposure to tariff-sensitive inputs.

Beyond direct cost impact, tariffs introduce administrative friction at ports of entry, extending lead times for critical reagents and instrument components and increasing working capital requirements for distributors and laboratories. Such delays can have downstream clinical consequences by affecting inventory planning and test availability, particularly for high-throughput or time-critical applications. Moreover, policy uncertainty around tariff schedules complicates long-range capital planning and investment in manufacturing capacity, which can slow decisions to scale new platforms or expand production lines.

At the same time, selective policy carve-outs for medical goods or negotiated exemptions can mitigate some pressure, while strategic nearshoring and collaborative supplier frameworks offer pathways to preserve product affordability and continuity of supply. Ultimately, organizations that proactively model tariff scenarios, diversify supplier portfolios, and invest in regulatory and customs expertise will be better positioned to sustain operations and protect access to essential diagnostic capabilities.

Deep segmentation insights linking product classes, assay technologies, end-user requirements, and clinical applications to strategic product and go-to-market choices

A granular view of the market requires attention to distinct product classes, technology modalities, end-user settings, and clinical applications, each of which follows its own adoption dynamics and operational constraints. Product segmentation shows a clear differentiation between instruments, reagents and consumables, and test kits, where instruments encompass both benchtop systems suited to centralized laboratories and portable devices optimized for decentralized or point-of-care environments. This split influences procurement cycles, maintenance requirements, and capital expenditure planning for healthcare providers.

Technology segmentation reveals varied pathways for innovation and commercialization. Immunoassays maintain a central role in many routine workflows due to robust clinical utility, while lateral flow assay formats continue to evolve with competitive and sandwich architectures that improve sensitivity and result presentation for rapid screening. Molecular diagnostics, including both polymerase chain reaction workflows and isothermal amplification techniques, are driving higher-sensitivity detection in compact formats, enabling clinical-grade results outside of traditional lab settings.

End-user segmentation underscores divergent needs across clinics, home care environments, hospitals, and laboratories, with each setting demanding different validation standards, throughput capabilities, and workflow integration. Application-driven segmentation further clarifies clinical priorities: cardiac markers such as creatine kinase-MB, myoglobin, and troponin require rapid, high-specificity readouts for acute care; diabetes management differentiates between Type 1 and Type 2 needs for monitoring and diagnostic precision; infectious disease testing spans bacterial, parasitic, and viral targets with varied sample types and turnaround requirements; oncology applications often require high analytical sensitivity and linkage to downstream therapeutic pathways. These layered segments inform product design, regulatory strategies, and commercial targeting across the diagnostic ecosystem.

Regional market dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific that dictate differentiated adoption, regulation, and supply strategies

Regional dynamics exert a profound influence on demand patterns, regulatory expectations, and supply chain strategies, with distinct trajectories observable across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, demand leans toward integrated platforms that support hospital networks and outpatient systems, with procurement influenced by payer reimbursement rules and a strong push for interoperability between diagnostics and electronic health records. This region also exhibits active investment in domestic manufacturing capacity and public-private partnerships to fortify supply chains.

Across Europe, the Middle East & Africa, regulatory harmonization efforts and variable healthcare infrastructure create heterogeneous market conditions that favor adaptable platforms and multi-modal assays. In some European markets, stringent regulatory oversight and centralized reimbursement mechanisms drive emphasis on rigorous clinical evidence, while in parts of the Middle East & Africa, infrastructure constraints heighten demand for robust, low-complexity, and transport-tolerant solutions.

The Asia-Pacific landscape is characterized by rapid adoption of decentralized testing and strong government-led initiatives to enhance local production, spanning large urban centers to rural networks. Diverse healthcare systems and varying levels of laboratory capacity create both scale opportunities and distribution challenges, encouraging strategic alliances with local players and investments in training and support services. Together, these regional nuances underline the need for differentiated commercial strategies, regulatory planning, and supply chain models that align with localized clinical and economic realities.

Competitive and strategic company-level behaviors shaping platform consolidation, partnership models, and manufacturing resilience in rapid diagnostics

Competitive dynamics in the rapid diagnostics space are shaped by a mix of established multinational manufacturers, niche specialists, reagent suppliers, and digitally native platform providers, each pursuing distinct strategic plays. Incumbent manufacturers leverage scale, broad product portfolios, and established distribution networks to serve hospital systems and reference laboratories, while smaller innovators focus on disruptive assay formats, streamlined manufacturing processes, or integration of digital health capabilities to capture pockets of rapid adoption.

Increasingly, strategic activity centers on partnerships and alliances that combine assay developers with instrument makers, data analytics firms, and logistics providers to deliver end-to-end solutions. Mergers and acquisitions remain a tactical path for acquiring complementary technologies or accelerating entry into new geographies, while licensing agreements and OEM arrangements provide flexible commercialization alternatives that reduce time-to-market. Companies are also investing in modular platform strategies that enable cross-application reuse of instrument bases, which supports faster assay rollouts and reduces per-unit production complexity.

Supply chain stewardship and regulatory expertise have become differentiators as organizations seek to ensure uninterrupted reagent availability and compliance across multiple jurisdictions. Firms that integrate clinical evidence generation, payer engagement, and scalable manufacturing are more successful at converting product innovation into sustainable market positions, while those that lag on service, support, or evidence development face adoption headwinds.

Actionable strategic recommendations for diagnostics leaders to strengthen portfolios, secure supply chains, demonstrate clinical value, and scale commercial models

Leaders in the diagnostics industry must translate market insights into concrete actions to capture opportunity and mitigate risk. First, organizations should prioritize portfolio diversification across instruments, reagents, and test kits while ensuring cross-platform compatibility to maximize addressable use cases. Investing in modular design and platform commonality reduces development cycle time and supports flexible manufacturing responses. Second, supply chain strategies should be reassessed through multi-sourcing, regionalization, and strategic inventory buffers to reduce exposure to trade policy shocks and logistical bottlenecks.

Third, vendors must deepen regulatory and clinical evidence capabilities by integrating real-world performance studies and health-economic analyses into product launches. Demonstrating outcomes and cost-effectiveness to payers accelerates coverage decisions and supports premium positioning. Fourth, commercialization models should shift toward value-driven offerings that bundle testing hardware with consumables, data services, and managed support to create recurring revenue and stronger customer relationships. Fifth, digital integration of diagnostics into electronic health records and telehealth workflows must be a priority to enhance utility and adoption in decentralized settings.

Finally, active engagement with policymakers and industry consortia can shape pragmatic trade and regulatory outcomes, protecting patient access while enabling sustainable business models. Executing these recommendations requires cross-functional alignment and disciplined investment prioritization to convert strategic intent into market advantage.

A rigorous mixed-methods research approach combining primary stakeholder interviews, secondary evidence synthesis, supply chain mapping, and scenario modeling for robust insights

The research behind these insights combines primary stakeholder engagement, structured secondary analysis, and targeted scenario modeling to deliver a multidimensional view of the rapid diagnostics landscape. Primary inputs were collected through interviews with clinicians, laboratory directors, procurement experts, and industry executives, providing firsthand perspectives on workflow priorities, adoption barriers, and technology preferences. Secondary analysis synthesized regulatory guidance, published clinical literature, patent landscapes, and public policy developments to contextualize market-facing observations within scientific and compliance frameworks.

Supply chain mapping and supplier risk assessment were used to identify critical nodes and common points of disruption, while technology readiness evaluations distinguished near-term deployable platforms from early-stage innovations requiring additional validation. Tariff and trade impact was assessed through scenario-based modeling that considered likely policy permutations and their operational consequences, enabling pragmatic recommendations for mitigation.

Throughout, findings were triangulated across data sources and validated with subject-matter experts to ensure robustness. Quality assurance measures included traceability of primary quotes, cross-referencing regulatory citations, and iterative peer review to refine conclusions and ensure actionable relevance for stakeholders making commercial, investment, or procurement decisions.

Concluding synthesis of strategic imperatives that connect diagnostic innovation, operational resilience, regulatory alignment, and commercial execution

In conclusion, the rapid diagnostics ecosystem presents a compelling mix of opportunity and complexity that requires strategic clarity, operational resilience, and evidence-driven commercialization. Advances in molecular methods, improved lateral flow formats, and the proliferation of portable instrumentation are expanding testing access and enabling more immediate clinical interventions outside traditional laboratory settings. At the same time, regulatory change, payer expectations, and trade policy dynamics are creating new constraints and considerations for developers and distributors alike.

Organizations that succeed will be those that align product innovation with rigorous clinical validation, cultivate adaptive supply chains, and pursue commercial models that emphasize outcomes and recurring value. Regional nuance demands differentiated approaches to market entry and partnership, while tariff-related uncertainty highlights the importance of sourcing flexibility and customs expertise. Above all, an integrated strategy that marries technical excellence with pragmatic execution-covering manufacturing, regulatory, reimbursement, and clinician engagement-will be essential to translate technological promise into sustained impact on patient care.

These conclusions underscore the need for focused investments and cross-functional coordination to capture the gains offered by rapid diagnostics while safeguarding continuity of access and clinical utility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rapid Diagnostics Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Benchtop
    • 8.1.2. Portable
  • 8.2. Reagents & Consumables
  • 8.3. Test Kits

9. Rapid Diagnostics Market, by Technology

  • 9.1. Immunoassay
  • 9.2. Lateral Flow Assay
    • 9.2.1. Competitive
    • 9.2.2. Sandwich
  • 9.3. Molecular Diagnostics
    • 9.3.1. Isothermal Amplification
    • 9.3.2. Pcr

10. Rapid Diagnostics Market, by End User

  • 10.1. Clinics
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Laboratories

11. Rapid Diagnostics Market, by Application

  • 11.1. Cardiac Markers
    • 11.1.1. Creatine Kinase Mb
    • 11.1.2. Myoglobin
    • 11.1.3. Troponin
  • 11.2. Diabetes
    • 11.2.1. Type 1 Diabetes
    • 11.2.2. Type 2 Diabetes
  • 11.3. Infectious Diseases
    • 11.3.1. Bacterial Infections
    • 11.3.2. Parasitic Infections
    • 11.3.3. Viral Infections
  • 11.4. Oncology

12. Rapid Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Rapid Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Rapid Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Rapid Diagnostics Market

16. China Rapid Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. ACON Laboratories, Inc.
  • 17.7. Becton, Dickinson and Company
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. bioMerieux SA
  • 17.10. Danaher Corporation
  • 17.11. DiaSorin S.p.A.
  • 17.12. EKF Diagnostics Holdings plc
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. Hologic, Inc.
  • 17.15. QIAGEN N.V.
  • 17.16. QuidelOrtho Corporation
  • 17.17. Siemens Healthineers AG
  • 17.18. Sysmex Corporation
  • 17.19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RAPID DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RAPID DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BENCHTOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COMPETITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COMPETITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COMPETITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SANDWICH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SANDWICH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SANDWICH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CREATINE KINASE MB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CREATINE KINASE MB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CREATINE KINASE MB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TROPONIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TROPONIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TROPONIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 197. GCC RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GCC RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GCC RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 207. GCC RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 230. G7 RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. G7 RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. G7 RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. G7 RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 240. G7 RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. NATO RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 244. NATO RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. NATO RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 251. NATO RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)